{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:53:24Z","timestamp":1791140004478,"version":"4.1.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>A key issue for the adjuvant treatment of patients with melanoma is the assessment of the effect of treatment on relapse, survival, and quality of life (QOL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare QOL in patients with resected melanoma at high risk for relapse who were treated with adjuvant pembrolizumab vs standard of care with either ipilimumab or high-dose interferon \u03b1 2b (HDI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The S1404 phase 3 randomized clinical trial was conducted by the SWOG Cancer Research Network at 211 community\/academic sites in the US, Canada, and Ireland. Patients were enrolled from December 2015 to October 2017. Data analysis for this QOL substudy was completed in March 2022. Overall, 832 patients were evaluable for the primary QOL end point.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Patients were randomized (1:1) to treatment with adjuvant pembrolizumab vs standard of care with ipilimumab\/HDI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Quality of life was assessed for patients at baseline and cycles 1, 3, 5, 7, and 9 after randomization using the Functional Assessment of Cancer Therapy (FACT) Biological Response Modifiers (FACT-BRM), FACT-General, Functional Assessment of Chronic Illness Therapy\u2013Diarrhea, and European QOL 5-Dimension 3-Level scales. The primary end point was the comparison by arm of cycle 3 FACT-BRM trial outcome index (TOI) scores using linear regression. Linear-mixed models were used to evaluate QOL scores over time. Regression analyses included adjustments for the baseline score, disease stage, and programmed cell death ligand 1 status. A clinically meaningful difference of 5 points was targeted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 1303 eligible patients (median [range] age, 56.7 [18.3-86.0] years; 524 women [40.2%]; 779 men [59.8%]; 10 Asian [0.8%], 7 Black [0.5%], 44 Hispanic [3.4%], and 1243 White [95.4%] individuals), 1188 (91.1%) had baseline FACT-BRM TOI scores, and 832 were evaluable at cycle 3 (ipilimumab\/HDI\u2009=\u2009267 [32.1%]; pembrolizumab\u2009=\u2009565 [67.9%]). Evaluable patients were predominantly younger than 65 years (623 [74.9%]) and male (779 [58.9%]). Estimates of FACT-BRM TOI cycle 3 compliance did not differ by arm (ipilimumab\/HDI, 96.0% vs pembrolizumab, 98.3%; <jats:italic>P<\/jats:italic>\u2009=\u2009.25). The adjusted cycle 3 FACT-BRM TOI score was 9.6 points (95% CI, 7.9-11.3; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) higher (better QOL) for pembrolizumab compared with ipilimumab\/HDI, exceeding the prespecified clinically meaningful difference. In linear-mixed models, differences by arm exceeded 5 points in favor of pembrolizumab through cycle 7. In post hoc analyses, FACT-BRM TOI scores favored the pembrolizumab arm compared with the subset of patients receiving ipilimumab (difference, 6.0 points; 95% CI, 4.1-7.8; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) or HDI (difference, 17.0 points; 95% CI, 14.6-19.4; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This secondary analysis of a phase 3 randomized clinical trial found that adjuvant pembrolizumab improved QOL vs treatment with adjuvant ipilimumab or HDI in patients with high-risk resected melanoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02506153\">NCT02506153<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.5486","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T16:33:35Z","timestamp":1669221215000},"page":"251","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma"],"prefix":"10.1001","volume":"9","author":[{"given":"Joseph M.","family":"Unger","sequence":"first","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Darke","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Othus","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thach-Giao","family":"Truong","sequence":"additional","affiliation":[{"name":"Kaiser Perm Northern California, Vallejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Khushalani","sequence":"additional","affiliation":[{"name":"H. Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Kendra","sequence":"additional","affiliation":[{"name":"Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl D.","family":"Lewis","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Faller","sequence":"additional","affiliation":[{"name":"Heartland NCORP\/Missouri Baptist Medical Center, St Louis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Funchain","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth I.","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad A.","family":"Tarhini","sequence":"additional","affiliation":[{"name":"H. Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"The University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon","family":"Sondak","sequence":"additional","affiliation":[{"name":"H. Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha R.","family":"Guild","sequence":"additional","affiliation":[{"name":"AIM at Melanoma, San Rafael, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Grossmann","sequence":"additional","affiliation":[{"name":"Merck and Co, Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna P.","family":"Patel","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi220069r1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1200\/JCO.2001.19.3.812","article-title":"Patient preferences for adjuvant interferon alfa-2b treatment.","volume":"19","author":"Kilbridge","year":"2001","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi220069r2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008955.pub2","article-title":"Interferon alpha for the adjuvant treatment of cutaneous melanoma.","author":"Mocellin","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"coi220069r3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi220069r4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"coi220069r5","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"19","key":"coi220069r6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"coi220069r7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant pembrolizumab versus IFNa2b or ipilimumab in resected high-risk melanoma.","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"issue":"26","key":"coi220069r8","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"coi220069r9","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma.","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"coi220069r10","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti\u2013PD-1\/PD-L1 treatment for malignancies: a meta-analysis.","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"issue":"32","key":"coi220069r11","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","article-title":"Patient-reported outcomes and the evolution of adverse event reporting in oncology.","volume":"25","author":"Trotti","year":"2007","journal-title":"J Clin Oncol"},{"issue":"17","key":"coi220069r12","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","article-title":"How accurate is clinician reporting of chemotherapy adverse effects? a comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.","volume":"22","author":"Fromme","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi220069r13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1046\/j.0269-4727.2003.00521.x","article-title":"Use of health-related quality of life in prescribing research: part 1: why evaluate health-related quality of life?","volume":"28","author":"Calvert","year":"2003","journal-title":"J Clin Pharm Ther"},{"issue":"36","key":"coi220069r14","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification.","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi220069r15","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension.","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"coi220069r16","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi220069r17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/B:QURE.0000015297.91158.01","article-title":"The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers.","volume":"13","author":"Bacik","year":"2004","journal-title":"Qual Life Res"},{"issue":"7","key":"coi220069r19","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","article-title":"Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study.","volume":"22","author":"Janssen","year":"2013","journal-title":"Qual Life Res"},{"issue":"3","key":"coi220069r20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model.","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"issue":"8","key":"coi220069r22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/(ISSN)1099-1611","article-title":"Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon.","volume":"13","author":"Trask","year":"2004","journal-title":"Psychooncology"},{"issue":"2","key":"coi220069r23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1524-4733.2005.08202.x","article-title":"Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument.","volume":"8","author":"Yost","year":"2005","journal-title":"Value Health"},{"key":"coi220069r24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/biomet\/81.3.471","article-title":"A class of pattern-mixture models for normal incomplete data.","volume":"81","author":"Little","year":"1994","journal-title":"Biometrika"},{"issue":"5","key":"coi220069r26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Pattern mixture models for longitudinal quality of life studies in advanced stage disease.","volume":"22","author":"Pauler","year":"2003","journal-title":"Stat Med"},{"issue":"3","key":"coi220069r27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"coi220069r28","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"33","key":"coi220069r29","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial.","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi220069r30","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(21)00081-4","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.","volume":"22","author":"Bottomley","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi220069r31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.19.01381","article-title":"Phase III study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alpha-2b for resected high-risk melanoma: North American Intergroup E1609.","volume":"38","author":"Tarhini","year":"2020","journal-title":"J Clin Oncol"},{"key":"coi220069r32","doi-asserted-by":"publisher","first-page":"e22078","DOI":"10.1200\/JCO.2020.38.15_suppl.e22078","article-title":"Patient-reported outcomes among patients with resected high-risk melanoma (AJCC7 IIIB, IIIC, M1a, M1b) randomized to low- or high-dose adjuvant ipilimumab (ipi) versus high-dose interferon alfa-2b (HDI): health-related quality of life (HRQL) analysis of ECOG-ACRIN E1609.","volume":"38","author":"Tarhini","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi220069r33","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1093\/annonc\/mdt274","article-title":"Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.","volume":"24","author":"Cort\u00e9s","year":"2013","journal-title":"Ann Oncol"},{"issue":"25","key":"coi220069r34","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177lu-dotatate in the phase III NETTER-1 trial.","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi220069r35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"coi220069r25","doi-asserted-by":"crossref","DOI":"10.1201\/9781420061185","volume-title":"Design and Analysis of Quality of Life Studies in Clinical Trials","author":"Fairclough","year":"2010","edition":"2nd ed"},{"key":"coi220069r18","unstructured":"FACIT Group. Functional assessment of chronic illness therapy\u2014diarrhea. Accessed March 30, 2021. https:\/\/www.facit.org\/measures\/FACIT-D"},{"key":"coi220069r21","unstructured":"EuroQol. EQ-5D-3L: about. Accessed March 30, 2021. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-3l-about\/"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2798988\/jamaoncology_unger_2022_oi_220069_1675884586.98431.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T16:03:35Z","timestamp":1676563415000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2798988"}},"subtitle":["A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.5486","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}